Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
Liaw. Yun-Fan YF
Key Findings
- Thymosin‑alpha‑1 enhances Th1 immune responses and T‑cell function
- It may improve outcomes in chronic hepatitis B patients, particularly those not responding to standard antivirals
- Preliminary monotherapy and combination trials with interferon show encouraging results
Practical Outcomes
- For biohackers, thymosin‑alpha‑1 could be an experimental immune‑support tool for hepatitis B, but there’s no clear protocol or safety data yet. It’s not currently a proven, actionable supplement for general longevity or performance goals.
Summary
Thymosin‑alpha‑1 (thymalfasin) is a peptide that can boost certain immune cells and might help people with chronic hepatitis B, especially when standard drugs don’t work well. Early studies combining it with interferon look promising, but details on dosing or real‑world use are still missing.
Abstract
Chronic hepatitis B virus (HBV) infection is a serious clinical problem because of its worldwide distribution and potential adverse sequelae. Globally, there are approximately 350 million people infected with chronic HBV, 75% of whom live in the Asia-Pacific region. Interferon-alfa and direct antiviral agents such as lamivudine and adefovir are effective in the therapy of chronic HBV infection but the efficacy is far from satisfactory, particularly in perinatally infected patients, patients with lower ALT levels and those with HBeAg-negative chronic hepatitis B. Thymalfasin (thymosin-alpha1) is an immunoregulatory agent able to enhance Th1 response. It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising.
Study Information
pubmed
2004
2004-12-01T00:00:00.000Z
10.1111/j.1440-1746.2004.03633.x
24
18